Biocon FDA Approval for JOBEVNE Biosimilar Marks a Big Win in Cancer Care
Biocon Biologics has received U.S. FDA approval for JOBEVNE, a biosimilar to the widely used cancer drug Avastin (bevacizumab). This green light marks Biocon’s seventh biosimilar approved in the U.S., reinforcing its global leadership in affordable biologics.
JOBEVNE works by blocking VEGF – vascular endothelial growth factor – a protein that helps tumors grow new blood vessels. By cutting off the blood supply, the drug helps slow or stop the growth of certain cancers, including colorectal, lung, kidney, and brain cancers.
The approval strengthens Biocon’s oncology portfolio, which already includes OGIVRI (trastuzumab) and FULPHILA (pegfilgrastim). These treatments are used for breast cancer and to reduce infection risk during chemotherapy, respectively.
Also Read: 506 School Girls Vaccinated in HPV Drive to Prevent Cervical Cancer in Gautam Budh Nagar!
Already Making Waves in Europe and Canada
In other parts of the world, JOBEVNE is known as ABEVMY. It is already available in Europe and Canada, where it has been helping cancer patients access more affordable treatments without compromising on quality.
Now, with Biocon FDA approval JOBEVNE biosimilar in the U.S., the company is set to tap into a major pharmaceutical market. U.S. sales of Avastin were around $2 billion in 2023, according to IQVIA, making this approval a high-stakes milestone for Biocon.
CEO Celebrates a Major Milestone
Shreehas Tambe, CEO and Managing Director of Biocon Biologics, called the approval a major validation of the company’s scientific expertise. “It reflects our strong commitment to make affordable biologics available to patients globally,” he said.
This move is especially important in cancer treatment, where the cost of care can be overwhelming. Biosimilars like JOBEVNE offer a cost-effective alternative to expensive biologics, potentially saving lives and healthcare dollars.
Challenges Still Remain for Biocon
Despite the regulatory success, Biocon’s financial results tell a mixed story. In Q3 FY2024, the company’s net profit dropped by 96.2% to ₹25.10 crore, even though net sales rose by 6.3% to ₹3773 crore. These figures suggest increasing costs or investment in R&D and global expansion.
On Wednesday, April 9, Biocon shares fell 5.33% to ₹305.20. However, the Indian stock market remains closed today due to Shri Mahavir Jayanti.
The Road Ahead for JOBEVNE and Biocon
With JOBEVNE now approved in the U.S., Biocon has the opportunity to make a real impact on the lives of cancer patients. It also gives the company a shot at tapping into a blockbuster market, especially as the demand for biosimilars continues to grow globally.
As the company looks ahead, its mission remains clear: make complex therapies accessible and affordable—not just in India, but around the world.
